Multiple sclerosis (MS) patients often report that heat makes their symptoms worse. There is anecdotal evidence that the opposite, body cooling, may make MS symptoms better. The goal of this study was to determine whether core body temperature cool ing compared to placebo treatment produced objective changes on the neurologic exam ination, and affected immune parameters, in MS patients. Eleven relapsing-remitting patients who reported heat sensitivity underwent cooling or sham cooling using a com mercially available active liquid flow cooling garment. Clinical parameters of visual acu ity, timed walk, muscle strength, and coordination, and immune parameters of cytokine production were examined one hour before and after treatment. Cooling produced a sig nificant improvement in acuity, timed walk, and muscle strength compared to sham cooling. Cooling, but not sham cooling, also decreased cytokine production by MS peripheral blood cells. These results suggest that cooling can result in objective clinical improvements in several functional systems of heat-sensitive MS patients. In addition to a clinical effect, cooling may also have an immune effect on MS.
Anderson DW, Ellenberg JH, Leventhal CM, Reingold SC, Rodriguez M, Silberberg DH. Revised estimate of the prevalence of multiple sclerosis in the United States. Ann Neurol1992; 31:333-36.
2.
Weinshenker BG, Bass B., Rice Gpa, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain1989;112:133-46.
3.
Minden SL, Marder WD, Harrold LN, Dor A.Multiple sclérosis. A statistical portrait: a compendium of data on demographics, disability, and health service utilization in the United States. Cam-bridge, MA: Abt. Associates, 1993.
4.
Waksman BHMultiple sclerosis: more genes versus environment. Nature1995;377:105-106.
5.
Jacobs L., Cookfair D., Rudick R., et al. Results of a phase III trial of intramuscular recombinant beta interferon as treatment for multiple sclerosis (abstr). Ann Neurol1994;36:259.
6.
Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology1994;45:1268-76.
7.
The IfnbMultiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology1995;45:1277-85.
8.
Guthrie TCVisual and motor changes in patients with multiple sclerosis. A result of induced changes in environmental temperature. Arch Neurol Psychiatry1951;65:437-51.
9.
Davis FA, Michael JA, Tomaszewski JS, Fluctuations in multiple sclerosis related to circadian temperature variations . Dis Nerv Sys1973;34:33-36.
10.
Nelson DA, Jeffreys WH, McDowell F.Effects of induced hyperthermia in some neurological diseases. Arch Neurol Psychiatry1958;79:31-39.
11.
Nelson DA, Jeffreys WH, McDowell F.Effects of induced hyperthermia on patients with multiple sclerosis . J Neurol Neurosurg Psychiatry1959;22:113-16.
12.
Davis FA, Michael JA, Neer D.Serial hyperthermia testing in multiple sclerosis: a method of monitoring subclinical fluctuations. Acta Neurol Scand1973;49:63-74.
13.
Michael JA, Davis FAEffects of induced hyperthermia in multiple sclerosis: differences in visual acuity during heating and recovery phases. Acta Neurol Scand1973;49(S2):141-51.
14.
Berger JR, Sheremata WAPersistent neurological deficit precipitated by the hot bath test . JAMA1983;249:1751-53.
15.
Thompson DSBlurring of vision in exercise. Trans Ophthalmol Soc UK1966;86:479-92.
16.
Perkin GD, Rose FCUhtoff's symptom. Brit J Ophthal1976; 60:60-63.
17.
Van Diemen HAM , Van Dongen MM, DammersJWHH, Polman CH. Increased visual impairment after exercise (Uhtoff's phenomenon) in multiple sclerosis: therapeutic possibilities . Eur Neurol1992;32:231-34.
Watson CWEffect of lowering body temperature on the symptoms and signs of multiple sclerosis. New Engl J Med1959; 261:1253-59.
20.
Hopper CL, Matthew CG, Cleeland CSSymptom instability and thermoregulation in multiple sclerosis. Neurology1972; 22:142-48.
21.
Geller M.Appearance of signs and symptoms of multiple sclerosis in response to cold. Mt. SinaiJ Med1974;41:127-30.
22.
Scherokman BT, Selhorst JB, Waybright EA, Jabbari B, Bryan GE, Maitland CG. Improved optic nerve conduction with ingestion of ice water. Ann Neurol1985;17:418-19.
23.
PoserCM, Paty DW, Scheinberg L., et al. New diagnostic criteria for multiple sclerosis: guidelines for research proposals. Ann Neurol1983;13:227-31.
24.
Fotino M., Merson EJ, Allen FHMicromethod for rapid separation of lymphocytes from peripheral blood . Ann Clin Lab Sci1971;1:131-33.
25.
Syndulko K. , Woldanski A, Baumhefner RW, Tourtellotte WW. Acute effects of cooling in multiple sclerosis: pilot study to compare two cooling garments (abstr). Neurology1995; 45(S4):A351.
Rasminsky M.The effects of temperature on conduction in demyelinated single nerve fibers. Arch Neurol1973;28:287-92.
28.
Schauf CL, Davis FAImpulse conduction in multiple sclerosis: a theoretical basis for modification by temperature and pharmacological agents. J Neurol Neurosurg Psychiatry1974;37: 152-61.
29.
Lederman HM , Brill CRMurphy P.Interleukin 1-driven secretion of interleukin 2 is highly temperature sensitive. J Immunol1987;138:3808-11.
30.
Haeffner-Cavaillon N., Roussellier N., Ponzio O., et al. Induction of interleukin-1 production in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg1989;98:1100-1106.
31.
Menasche P. , Haydar S., Peynet J., et al. A potential mechanism of vasodilation after warm heart surgery. The temperature dependent release of cytokines. J Thorac Cardiovasc Surg1994;107:292-99.
32.
Pober JSCytokine—mediated activation of vascular endothelium. Am J Pathol1988;133:426-33.
33.
Dinarello CAInterleukin-1 and its biological related cytokines . Adv Immunol1989;44:153-203.
34.
Quagliarello VJ, Wispelwey B., Long WJ Jr, Scheld WM. Recombinant human interleukin-1 induces meningitis and blood-brain barrier injury in the rat . J Clin Invest1991;44:1360-66.
35.
Brosnan CF, Cannella B, Battistini L, Raine CS. Cytokine localization in multiple sclerosis lesions: correlation with adhesion molecule expression and reactive nitrogen species. Neurology1995;45(S6):S16-S21.
36.
Jacobs CA, Baker PE, Roux ER, et al. Experimental autoimmune encephalomyelitis is exacerbated by IL-1 and suppressed by soluble IL-1 receptors. J Immunol1991;146:2983-89.
37.
Waldmann TAThe IL-2/IL-2 receptor system: a target for rational immune intervention . Immunol Today1993;14:264-70.
38.
Caruso C., Candore G., Cigna D., et al. Biological significance of soluble IL-2 receptors. Mediators ofInflammation1993;2:3-21.
39.
Chalon MP, Sindic Cjm, Laterre ECSerum and CSF levels of soluble interleukin-2 receptors in MS and other neurological diseases: a reappraisal. Acta Neurol Scand1993;87:77-82.
40.
Harrington L., Affleck G., Urrows S., et al. Temporal covariation of soluble interleukin-2 receptor levels, daily stress, and disease activity in rheumatoid arthritis . Arthritis Rheum1993;36: 199-203.
